Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Depreciation & Amortization (CF) (2016 - 2025)

IGC Pharma (IGC) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $119000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 17.93% to $119000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $571000.0, a 9.51% decrease, with the full-year FY2025 number at $618000.0, down 2.98% from a year prior.
  • Depreciation & Amortization (CF) was $119000.0 for Q3 2025 at IGC Pharma, down from $141000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $172000.0 in Q4 2022 to a low of $119000.0 in Q3 2025.
  • A 5-year average of $157315.8 and a median of $160000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 121.33% in 2021, then fell 17.93% in 2025.
  • IGC Pharma's Depreciation & Amortization (CF) stood at $166000.0 in 2021, then rose by 3.61% to $172000.0 in 2022, then dropped by 6.98% to $160000.0 in 2023, then decreased by 1.88% to $157000.0 in 2024, then dropped by 24.2% to $119000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Depreciation & Amortization (CF) are $119000.0 (Q3 2025), $141000.0 (Q2 2025), and $154000.0 (Q1 2025).